Analytical/CMC (Potency)

Potency Assays for Cell & Gene Therapy Products

Potency Assay Development

The preferred method for determining potency is a single, quantitative biological assay. However, due to the complex nature of CGT products, this approach may not always be sufficient. In this case, an alternative approach of using a non-biological assay and/or a combination of biological and non-biological assays (i.e. an assay matrix) may be used. At least one assay used to measure potency should be quantitative, and there should be scientifically sound data to correlate assay results to relevant product-specific biological activity.

 

Roadmap of In Vitro Potency Assays for CGT Products: Tools & Techniques

 

 

Potency assay development should start as early as possible in the product’s life cycle to allow time for evaluating multiple assays, generating data on product stability and consistency, and collecting data to support correlation studies if needed. As the product advances through clinical phases, so should the potency assay with regards to demonstrating biological relevance and establishing acceptance criteria. This phase-appropriate approach allows continuous improvement and optimization of the potency assay, which will enable consistent lot release during clinical trials and streamlined regulatory submission.

 

 

Steps to Potency Assay Validation

For more information, request a download of ACF Bioservices’ Potency Assay Guide: Understanding Potency Assay Validation, FDA Requirements